MYD88 and B-cell chronic lymphocytic leukemia: Several therapeutic agents that directly or indirectly inhibit the MYD88 L265P oncogenic activity in CLL have emerged, such as BTK inhibitors, IRAK4 inhibitors [45], and immunomodulatory oligonucleotides [6,53].